Comparison

CBLB Antibody (Center) Blocking Peptide

Item no. ABC-BP8668c
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Lavagna-Sevenier,C., et.al., J. Biol. Chem. 273 (24), 14962-14967 (1998)Yokoi,N., et.al., Biochem. Biophys. Res. Commun. 368 (1), 37-42 (2008)
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias E3 ubiquitin-protein ligase CBL-B,632-,Casitas B-lineage lymphoma proto-oncogene b,RING finger protein 56,SH3-binding protein CBL-B,Signal transduction protein CBL-B,CBLB,RNF56
Similar products CBLB, E3 ubiquitin-protein ligase CBL-B, Casitas B-lineage lymphoma proto-oncogene b, SH3-binding protein CBL-B, Signal transduction protein CBL-B, RNF56, RING finger protein 56, 632-
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence used to generate the antibody AP8668c was selected from the Center region of human CBLB. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background
E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. It also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. It may also be involved in EGFR ubiquitination and internalization.
Gene Name
CBLB
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close